Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Non-Current Deffered Revenue (2024 - 2025)

Prime Medicine's Non-Current Deffered Revenue history spans 2 years, with the latest figure at $58.1 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 8.05% year-over-year to $58.1 million; the TTM value through Dec 2025 reached $58.1 million, down 8.05%, while the annual FY2025 figure was $58.1 million, 8.05% down from the prior year.
  • Non-Current Deffered Revenue reached $58.1 million in Q4 2025 per PRME's latest filing, down from $59.8 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $63.2 million in Q4 2024 to a low of $58.1 million in Q4 2025.